Genmab — December 2025
-
Results from two arms of the EPCORE
NHL-2 trial, evaluating first-line, fixed-treatment duration epcoritamab in combination with chemotherapies, demonstrated overall response rates (ORR) of 93% (Arm 
and 98% (Arm 1) in patients with newly-diagnosed DLBCL, while a third arm (Arm 3) demonstrated a three-year overall survival (OS) rate of 96% in patients with FL following first-line combination treatment. -
Det er data som viser generelt høje responsrater, dybe og langvarige remissioner samt en håndterbar sikkerhedsprofil, især i udfordrende patientgrupper som ældre eller højrisikopatienter. Umiddelbart ser det ud til at epcoritamab på de fleste parametre giver baghjul til glofitamab og mosunetuzumab. Patientvenligheden med subkutan fixed-duration er et yderligere plus.
-
Godmorgen
-
https://www.onclive.com/view/epcoritamab-plus-r-mini-chop-may-aid-in-treatment-of-elderly-patients-with-first-line-dlbcl Epcoritamab Plus R-mini-CHOP May Aid in Treatment of Elderly Patients with First-Line DLBCL
-
-
-
Genmab Presents Pivotal Phase 3 Data from EPCORE
FL-1 Trial Demonstrating Clinical Benefit of EPKINLY (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma https://ir.genmab.com/news-releases/news-release-details/genmab-presents-pivotal-phase-3-data-epcorer-fl-1-trial -
Det er stærke data fra EPCORE FL-1-studie. De demonstrerer klare kliniske fordele ved epcoritamab i kombination med rituximab og lenalidomid (R²) sammenlignet med R² alene som standardbehandling for patienter med relapsed/refractory FL efter mindst én tidligere linje. Sikkerhedsprofilen er håndterbar og i tråd med monoterapi.Samlet set balancerer sikkerheden de høje effektresultater godt, hvilket gør behandlingen velegnet til udsatte patienter uden at kompromittere livskvalitet markant.
-
Kan være game changer i relapsed FL. Det ligner en potentiel ny standard i anden linje
Epkinly + R² er markant bedre og længerevarende effekt med acceptabel sikkerhed.
-
Godmorgen
-
Genmab viser lovende resultater i fase 3-studie med kræftmiddel https://proinvestor.com/investornyt/1390915/genmab-viser-lovende-resultater-i-fase-3-studie-med-kraeftmiddel
-
Fra MW "Genmab har fået hævet sit kursmål til 2050 kr. fra 1650 kr. hos JP Morgan.
I samme ombæring fastholdes anbefalingen "neutral", det fremgår af data fra Bloomberg News.
Fredag faldt Genmab-aktien med 1,5 pct. til 2032 kr. Samlet er aktien i Genmab steget 36,2 pct. i år."
-
#ASH25 | PRESENTATION
Lori Leslie shares 3-year results from the phase Ib/II EPCORE NHL-2 trial, of 1L epcoritamab with rituximab + lenalidomide (Arm 6; n = 41) and epcoritamab maintenance monotherapy following SOC (Arm 7; n = 19), in patients with FL. https://x.com/lymphomahub/status/1997759594098295276
by chance,
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind